Document is current
Any future updates will be listed below
-
Authors
Marcella, Bianca M.
Hockey, Briana L.
Braun, Jessica L. https://orcid.org/0000-0002-9196-0757
Whitley, Kennedy C.
Geromella, Mia S.
Baranowski, Ryan W.
Watson, Colton J. F.
Silvera, Sebastian
Hamstra, Sophie I. https://orcid.org/0000-0001-8418-449X
Wasilewicz, Luc J.
Crozier, Robert W. E.
Marais, Amélie A. T.
Kim, Kun Ho
Lee, Gabsang https://orcid.org/0000-0002-5052-5927
Vandenboom, Rene
Roy, Brian D. https://orcid.org/0000-0003-4638-5586
MacNeil, Adam J. https://orcid.org/0000-0002-4749-8120
MacPherson, Rebecca E. K. https://orcid.org/0000-0002-1577-2658
Fajardo, Val A. https://orcid.org/0000-0003-4500-3347
-
Funding
Funding for this research was provided by:
Canada Research Chairs
Brock University unrestricted funds (startup) Brock-Niagara Validation Prototyping and Manufacturing Applied Project Grant
- License Information
-
More Information
Article History
Received: 22 July 2023
Accepted: 25 October 2024
First Online: 25 November 2024
Competing interests
: The authors declare the following competing interests. A portion of this project, specifically the aged (28–30 weeks) tideglusib experiments, was funded by AMO-Pharma in partnership with a Brock-Niagara Validation Prototyping and Manufacturing Applied Project Grant (1:2 monetary ratio). AMO-Pharma also provided the tideglusib for the aged tideglusib experiments. For all other experiments, tideglusib was purchased from Sigma Alrdich (SML0339).
